Hanall Biopharma Co

Hanall Biopharma Co Interest Coverage

The Interest Coverage Ratio of Hanall Biopharma Co (009420.KS) as of Nov 2, 2026 is 1.22. In the previous year, Interest Coverage Ratio was 0.86 — a change of 41.50% (higher).

Interest Coverage

1.22

YoY

41.50%

Last updated:

Interest Coverage Ratio of Hanall Biopharma Co is 2024 1.22 . Interest Coverage Ratio of Hanall Biopharma Co was 2023 0.86 . It decreases by 41.50% higher compared to the previous year.

The Hanall Biopharma Co Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
3.92 KRW
Jan 1, 2018
1.99 KRW
Jan 1, 2019
7.09 KRW
Jan 1, 2020
0.45 KRW
Jan 1, 2021
25.19 KRW
Jan 1, 2022
2.37 KRW
Jan 1, 2023
0.86 KRW
Jan 1, 2024
1.22 KRW
The Hanall Biopharma Co Interest Coverage history
YEARInterest CoverageYoY
1.22+41.50%
0.86-63.65%
2.37-90.59%
25.19+5,470.45%
0.45-93.63%
7.09+256.01%
1.99-49.11%
3.92+1,236.41%
0.29-101.14%
-25.78-419.41%
8.07—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hanall Biopharma Co Stock analysis

What does Hanall Biopharma Co do? The company Hanall Biopharma Co Ltd was founded in South Korea in 2000 and has since become a leading biopharmaceutical company. The business model of Hanall Biopharma is to develop and market innovative medical products that have the potential to help patients around the world. Hanall Biopharma has several divisions, including the development of biosimilars, where the company has extensive experience. Biosimilars are biological drugs that have a similar effect to an already approved biological drug but can be offered at a lower price. Hanall Biopharma is currently developing several biosimilars, including drugs for the treatment of breast cancer and rheumatoid arthritis. Another important area for Hanall Biopharma is the research and development of novel cancer drugs. The company works closely with renowned research institutes and clinics to identify and develop innovative treatment approaches. The goal is to create drugs that are both more effective and better tolerated than conventional cancer drugs. In addition to these areas, Hanall Biopharma also conducts research and development in many other fields, including neurodegenerative diseases such as Alzheimer's and Parkinson's, rare diseases, and infectious diseases. Hanall Biopharma has also established itself as a provider of research services. Here, the company offers its customers a wide range of services, ranging from drug discovery and development to clinical development. One of Hanall Biopharma's most well-known products is the cancer drug Monoclate-P. This medication is used to treat hemophilia, a rare blood disorder caused by reduced or absent blood clotting. Monoclate-P is the first recombinant factor VIII product manufactured in South Korea. Another significant product of Hanall Biopharma is the cancer drug Abraxane. Abraxane is a nanoparticle-based cancer drug used to treat breast cancer, lung cancer, and pancreatic cancer. Hanall Biopharma has acquired the licensing rights to Abraxane in South Korea and other Asian countries and successfully distributes the medication in these regions. Overall, it remains to be seen how the company Hanall Biopharma Co Ltd will develop in the future. However, given its clear focus on developing innovative medical products and its strong expertise in biotechnology, the future of the company looks promising. Hanall Biopharma Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hanall Biopharma Co stock

Interest Coverage Ratio of Hanall Biopharma Co is 1.22 in 2024.

Interest Coverage Ratio of Hanall Biopharma Co changed from 0.86 to 1.22, representing a 41.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Hanall Biopharma Co since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Hanall Biopharma Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Hanall Biopharma Co

All Key Metrics — Hanall Biopharma Co